Publications by authors named "Handan Onur"

Claim this Profile
I
Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study.
Tülay Canda, Ekrem Yavuz, Necmettin Özdemir, Sennur İlvan, Serpil Sak Dizbay, Handan Onur

Eur J Breast Health· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic serum vitamin D level is not a reliable prognostic factor for resectable breast cancer.
Dilsa Mizrak Kaya, Bengi Ozturk, Pinar Kubilay, Handan Onur, Gungor Utkan

Future Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG).
Ali Alkan, Zeynep Gulsum Guc, Filiz Cay Senler, Tugba Yavuzsen, Handan Onur

Support Care Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABO and Rh blood groups and risk of colorectal adenocarcinoma.
Yuksel Urun, Nuriye Yildirim Ozdemir, Gungor Utkan, Hakan Akbulut, Berna Savas, Handan Onur

Asian Pac J Cancer Prev· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).
Fikri İçli, Kadri Altundağ, Hakan Akbulut, Semra Paydaş, Gül Başaran, Handan Onur

Breast Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.
Yeşim Eralp, Leyla Kılıç, Gül Alço, Gül Başaran, Mutlu Doğan, Handan Onur

J Breast Health· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is obesity always a risk factor for all breast cancer patients? c-erbB2 expression is significantly lower in obese patients with early stage breast cancer.
Umut Mousa, Handan Onur, Gungor Utkan

Clin Transl Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
Fikri Icli, Hakan Akbulut, Handan Onur, Bulent Yalcin, Ahmet Demirkazık

Breast· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Dilek Dincol, Abdullah Buyukcelik, Mutlu Dogan, Hakan Akbulut, Mustafa Samur, Handan Onur

Med Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
Fikri Icli, Hakan Akbulut, Gungor Utkan, Bülent Yalcin, Dilek Dincol, Handan Onur

J Surg Oncol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
Güngör Utkan, Abdullah Büyükçelik, Bülent Yalçin, Hakan Akbulut, Ahmet Demirkazik, Handan Onur

Lung Cancer· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
Abdullah Büyükçelik, Handan Onur, Hakan Akbulut, Yalçin Bülent, Arzu Ensari

Tumori· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
Hakan Akbulut, Fikri Icli, Bulent Yalcin, Ahmet Demirkazik, Handan Onur

Exp Oncol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis